Stock ATOSSA GENETICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Atossa Genetics Inc Nasdaq

Equities

US04962H1005

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Atossa Genetics Inc
07-02 Atossa Therapeutics Names Heather Rees CFO MT
07-02 Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Atossa Therapeutics Names Heather Rees CFO
MT
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
AQ
Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer
CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2000 Dynamic Index
CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Microcap Value Index
CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2500 Growth Index
CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell Small Cap Comp Growth Index
CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 2500 Index
CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000 Index
CI
Atossa Therapeutics, Inc.(NasdaqCM:ATOS) added to Russell 3000E Value Index
CI
Atossa Therapeutics Doubles Z-Endoxifen Dose in Phase 2 Breast Cancer Study
MT
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
AQ
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
CI
Atossa Set to Join Russell 3000 Index Effective June 28, 2024
AQ
Atossa Therapeutics Set to Join Updated Russell 3000 Index
MT
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
AQ
Atossa to Present at the Sidoti Small-Cap Investor Conference
AQ
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
AQ
Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
CI
Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. Stock
  5. News Atossa Genetics Inc